Evidence map›Paper›PMID 34675501›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-Related Exacerbations.

Morgan Justice Fuoco, Richard A Mularski, Benjamin Wu, Chad Moretz, Mary Ann McBurnie, Richard H Stanford, Phillip Crawford, Daniel Gratie, Bianca Salas

Abstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Morgan Justice FuocoKaiser Permanente Center for Health Research, Science Programs Department, Portland, OR, USA.
Richard A MularskiKaiser Permanente Center for Health Research, Science Programs Department, Portland, OR, USA.ORCID 0000-0001-6979-2542
Benjamin WuGlaxoSmithKline, US Value Evidence and Outcomes, Research Triangle Park, Durham, NC, USA.
Chad MoretzGlaxoSmithKline, US Value Evidence and Outcomes, Research Triangle Park, Durham, NC, USA.ORCID 0000-0003-1828-1667
Mary Ann McBurnieKaiser Permanente Center for Health Research, Science Programs Department, Portland, OR, USA.ORCID 0000-0003-0314-220X
Richard H StanfordGlaxoSmithKline, US Value Evidence and Outcomes, Research Triangle Park, Durham, NC, USA.ORCID 0000-0001-5795-1147
Phillip CrawfordKaiser Permanente Center for Health Research, Science Programs Department, Portland, OR, USA.ORCID 0000-0003-0774-7898
Daniel GratieGlaxoSmithKline, US Value Evidence and Outcomes, Research Triangle Park, Durham, NC, USA.
Bianca SalasKaiser Permanente Center for Health Research, Science Programs Department, Portland, OR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is currently little research describing patient experience and continuity of care immediately prior, during, and following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). This analysis examined clinical characteristics, chronic obstructive pulmonary disease (COPD)‑related medication patterns and outpatient visits before and after an AECOPD.

methodsThis retrospective analysis used electronic health records, medical claims, and pharmacy dispensing data for patients within the Kaiser Permanente Northwest Health System. Patients with ≥1 AECOPD between January 1, 2015 and December 31, 2017 were identified. The most recent AECOPD was considered the index date. An AECOPD was defined as an inpatient hospitalization with a primary diagnosis of COPD, or respiratory failure with a secondary diagnosis of COPD, or an outpatient visit with a primary diagnosis of COPD and dispensing of respiratory-related antibiotics and/or oral corticosteroids ±5 days of the visit. Eligible patients were: ≥40 years old; ≥2 encounters within 12 months of each other or ≥1 hospitalization with primary or secondary COPD diagnosis, chronic bronchitis, or emphysema prior to index; and continuously enrolled ±90 days relative to index. COPD-related inhaled maintenance medication, rescue inhalers, oral corticosteroid use, and ambulatory visits were assessed 90-days pre- and post-index.

resultsThere were 2829 patients included (mean [standard deviation] age: 69.0 [10.5] years) who had an AECOPD (7% severe; 93% moderate). The percentage of patients on inhaled maintenance therapy increased from 60.6% pre-AECOPD to 68.8% post-AECOPD and increased from 60.0% to 87.4% among patients who experienced a severe AECOPD. COPD-related ambulatory visits increased more than four-fold for primary care and more than doubled for pulmonologist visits in the post-AECOPD period.

conclusionThe low proportion of patients observed with changes to controller and rescue medication (particularly following a moderate AECOPD), yet higher utilization of COPD-related ambulatory visits before and after an AECOPD suggests that there is opportunity to improve pharmacotherapy management.

Indexed as

Bronchitis, ChronicDelivery of Health Care, IntegratedPulmonary Disease, Chronic ObstructiveAdultAgedContinuity of Patient CareDisease ProgressionHumansRetrospective StudiesCOPDexacerbationquality of caretreatment patternstriple therapy

Identifiers

PMID34675501
PMCPMC8504477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.